The American Journal of Surgery
Volume 199, Issue 4 , Pages 459-465 , April 2010

Visfatin—a proinflammatory adipokine—in gallstone disease

  • Shen-Nien Wang, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
    • Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
    • Drs. Wang and Yeh contributed equally to this manuscript.
    • ,
  • Yao-Tsung Yeh, Ph.D.

      Affiliations

    • Department of Medical Technology, Fooyin University, Kaohsiung, Taiwan
    • Drs. Wang and Yeh contributed equally to this manuscript.
    • ,
  • Sen-Teh Wang, M.D.

      Affiliations

    • Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan
    • ,
  • Shih-Chang Chuang, M.D.

      Affiliations

    • Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
    • ,
  • Chao-Ling Wang, M.D.

      Affiliations

    • Department of Preventive Medicine, Koahsiung Medical University Hospital, Kaohsiung, Taiwan
    • ,
  • Ming-Lung Yu, M.D.

      Affiliations

    • Department of Internal Medicine, Hepatobiliary Division, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
    • ,
  • King-Teh Lee, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886-7-320-8171; fax: +886-7-321-6992

Received 26 August 2008 ,Revised 22 January 2009

References 

  1. Everhart JE, Khare M, Hill M, et al. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology. 1999;117:632–639
  2. Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic gallstones. Br J Surg. 2004;91:734–738
  3. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J. 2001;77:221–229
  4. Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best pract res clin Gastroenterol. 2006;20:981–996
  5. Donovan JM. Physical and metabolic factors in gallstone pathogenesis. Gastroenterol Clin North Am. 1999;28:75–97
  6. Hsing AW, Sakoda LC, Chua S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:s843–s857
  7. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007;128:837–847
  8. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591
  9. Tilg H, Moschen AR. Adipocytokines. Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–783
  10. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431–1437
  11. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–430
  12. McGlothlin JR, Gao L, Lavoie T, et al. Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet. 2005;43:127–141
  13. Wang SN, Yeh YT, Yu ML, et al. Hyperleptinaemia and hypoadiponectinaemia are associated with gallstone disease. Eur J Clin Invest. 2006;36:176–180
  14. Wang SN, Yeh YT, Yu ML, et al. Serum adiponectin levels in cholesterol and pigment cholelithiasis. Br J Surg. 2006;93:981–986
  15. Mantsch HH, Chapman D. Infrared Spectroscopy of Biomolecules. New York: John Wiley; 1996;
  16. Kleiner O, Ramesh J, Huleihel M, et al. A comparative study of gallstones from children and adults using FTIR spectroscopy and fluorescence microscopy. BMC Gastroenterol. 2002;2:3–16
  17. Trotman BW, Soloway RD. Pigment gallstone disease: summary of the National Institutes of Health -international workshop. J Hepatol. 1982;2:879–884
  18. Cetta F, Lombardo F, Giubbolini M, et al. Classification of gallstones and epidemiologic studies. Digest Dis Sci. 1995;40:2189–2191
  19. Choi KM, Lee JS, Kim EJ, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol. 2008;158:203–207
  20. Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond). 2008;114:275–288
  21. Filippattos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest. 2007;30:323–326
  22. Arner P. Visfatin—a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:28–30
  23. Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006;91:1578–1581
  24. Jin H, Jiang B, Tang J, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract. 2008;79:412–418
  25. Ye SQ, Somon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med. 2005;171:361–370
  26. Bajwa EK, Yu CL, Gong MN, et al. Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. Crit Care Med. 2007;35:1290–1295
  27. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004;113:1318–1327

 Supported by grant NSC 95-B to 2,314-B-037-046-from the National Science Council, ROC.

PII: S0002-9610(09)00137-8

doi: 10.1016/j.amjsurg.2009.01.014

The American Journal of Surgery
Volume 199, Issue 4 , Pages 459-465 , April 2010

Article Tools

* Image Usage & Resolution